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Introduction: The National Institute for Health and Care Excellence (NICE) recommended direct oral 
anticoagulants (DOACs) for a variety of indications as equal alternatives to warfarin, and stated that 
the patient's values and preferences should be used to guide choice of agent in a shared decision 
making process [1]. However, uptake of DOACs had been patchy and slow across the UK [2]. 
Identifying the perceived barriers to using DOACs could help to develop strategies to overcome 
these and enable their use where appropriate. 
Aim: The study aimed to investigate the attitudes and perceptions of professionals towards oral 
anticoagulation, and the choice between warfarin and the DOACs. 
Methods: One-to-one semi-structured interviews were conducted between May and July 2018. 
Participants were recruited using snowball and convenience sampling, across four NHS trusts and 
one Clinical Commissioning Group. Inclusion criteria were that participants should be either a 
hospital pharmacist, general practitioner, or cardiology or care of the elderly registrar or consultant, 
and involved in the initiation of oral anticoagulation. A topic guide was used to aid the interview 
process; this included questions regarding the participant’s role in prescribing anticoagulation, how 
they felt about the choices of oral anticoagulants, how they discussed this with patients, any 
concerns they had regarding DOACs, and if and how they used any materials to aid in shared 
decision making. Interviews were transcribed verbatim and analysed using framework analysis. 
Results: Thirteen interviews were carried out, lasting between 17 and 48 minutes, with an average 
length of 32 minutes. Table 1 shows participant characteristics. Current practice was found to be 
moving through a period of change, with a shift towards preference for DOACs, especially for 
patients with non-valvular atrial fibrillation (AF). The main themes identified were (1) an overarching 
theme of change, (2) barriers and facilitators to appropriate use of oral anticoagulants, (3) 
professional related factors affecting drug choice and (4) perceptions of the shared decision making 
process. Many professionals have a preferred DOAC which they use, but the reasons for preference 
vary. Perceived advantages of DOACs included a beneficial overall clinical effect in treating certain 
indications from evolving trial data, convenience due to reduced monitoring, and ability to use 
certain DOACs in compliance aids. Tools to aid the shared decision making process were not widely 
used, and there was a perception that shared decision making was not comprehensively 
approached. 
Table 1: Participant characteristics 
Role and specialty Number of participants 
Consultant – cardiology 1 male, 1 female 
Registrar – cardiology 1 male, 1 female 
Consultant – stroke 1 male, 1 female 
Consultant – care of the elderly 1 male, 1 female 
GP 1 male 
Hospital pharmacist 3 male, 1 female 
 
Conclusions: The landscape with regards to oral anticoagulation options was found to be in a period 
of change, and there appeared to be a move towards a preference for DOACs over warfarin. As the 
prescribing of oral anticoagulants is changing towards greater numbers of patients prescribed 
DOACs, there is a need to review the provision of anticoagulation services. One limitation in this 
study is that most participants were professionals from secondary care, with only one participant in 
primary care. Another limitation is that participants tended to mainly prescribe anticoagulation for 
AF, however attitudes and perceptions towards use of DOACs in other indications may differ. 
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